William Blair Brokers Lower Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – William Blair lowered their Q2 2025 earnings per share estimates for Axsome Therapeutics in a research report issued on Monday, July 14th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($1.00) for the quarter, down from their prior estimate of ($0.99). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics’ FY2025 earnings at ($3.30) EPS and FY2026 earnings at $1.71 EPS.

AXSM has been the topic of a number of other research reports. Morgan Stanley initiated coverage on Axsome Therapeutics in a report on Thursday, July 3rd. They set an “overweight” rating and a $190.00 price target on the stock. Oppenheimer initiated coverage on Axsome Therapeutics in a research note on Tuesday, June 3rd. They set an “outperform” rating and a $185.00 target price on the stock. Needham & Company LLC reduced their price target on Axsome Therapeutics from $153.00 to $150.00 and set a “buy” rating for the company in a research report on Monday, June 9th. Mizuho raised their price target on Axsome Therapeutics from $212.00 to $216.00 and gave the company an “outperform” rating in a report on Thursday, March 27th. Finally, Cantor Fitzgerald upgraded shares of Axsome Therapeutics to a “strong-buy” rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $172.33.

Axsome Therapeutics Trading Up 1.1%

Shares of NASDAQ:AXSM opened at $111.32 on Wednesday. The company has a quick ratio of 1.96, a current ratio of 2.03 and a debt-to-equity ratio of 3.48. The company’s 50-day moving average price is $106.40 and its 200 day moving average price is $108.77. The company has a market cap of $5.48 billion, a PE ratio of -19.29 and a beta of 0.46. Axsome Therapeutics has a fifty-two week low of $72.21 and a fifty-two week high of $139.13.

Insider Activity

In other news, COO Mark L. Jacobson sold 25,000 shares of Axsome Therapeutics stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $110.44, for a total value of $2,761,000.00. Following the transaction, the chief operating officer owned 5,783 shares of the company’s stock, valued at $638,674.52. The trade was a 81.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Hunter R. Murdock sold 7,500 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $100.26, for a total transaction of $751,950.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,437 shares of company stock worth $9,834,215. Corporate insiders own 22.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its position in shares of Axsome Therapeutics by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company’s stock worth $27,755,000 after purchasing an additional 5,438 shares during the period. Raymond James Financial Inc. purchased a new position in Axsome Therapeutics in the 4th quarter worth about $14,771,000. HighTower Advisors LLC acquired a new stake in Axsome Therapeutics during the 4th quarter worth about $1,139,000. Swiss National Bank raised its holdings in Axsome Therapeutics by 1.5% during the 4th quarter. Swiss National Bank now owns 61,400 shares of the company’s stock worth $5,195,000 after buying an additional 900 shares during the period. Finally, Royce & Associates LP lifted its stake in Axsome Therapeutics by 64.4% during the fourth quarter. Royce & Associates LP now owns 37,000 shares of the company’s stock valued at $3,131,000 after buying an additional 14,500 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.